Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting

References

• McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–7
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177–8
   PubMed Web of Science ®Google Scholar
• Helbert M, Bodger S, Cavenagh J, et al. Optimising testing for phospholipid antibodies. J Clin Pathol 2001; 54: 693–8
   PubMed Web of Science ®Google Scholar
• Marai I, Gilburd B, Blank M, Shoenfeld Y. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies 2003; 12: 57–62
   PubMedGoogle Scholar
• Audrain M A, Colonna F, Morio F, Hamidou M A, Muller J Y. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1. Rheumatology (Oxford) 2004; 43: 181–5
   PubMed Web of Science ®Google Scholar
• Bertolaccini M L, Gomez S, Pareja J F, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64: 1639–43
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717–23
   PubMed Web of Science ®Google Scholar
• de Laat B, Derksen R H, T U R, de Groot P G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540–5
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147–52
   PubMed Web of Science ®Google Scholar
• Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231–8
   PubMed Web of Science ®Google Scholar
• Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160–5
   PubMed Web of Science ®Google Scholar
• Wilson W A, Gharavi A E, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–11
   PubMed Web of Science ®Google Scholar
• Lockshin M D, Sammaritano L R, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440–3
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin M D, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306
   PubMed Web of Science ®Google Scholar
• Harris E N, Gharavi A E, Patel S, Hughes G RV. Evaluation of the anticardiolipin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987; 68: 215–22
   PubMed Web of Science ®Google Scholar
• Harris E N, Pierangeli S S. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269–75
   PubMed Web of Science ®Google Scholar
• Favaloro E J, Wong R C, Jovanovich S, Roberts-Thomson P. A review of beta2-glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program. Am J Clin Pathol 2007; 127: 441–8
   PubMed Web of Science ®Google Scholar
• Favaloro E J, Bonar R, Sioufi J, et al. Multi-laboratory testing of thrombophilia: Current and past practice in Australasia as assessed through the RCPA Haematology QAP. Semin Thromb Hemost 2005; 31: 49–58
   PubMed Web of Science ®Google Scholar
• Favaloro E J, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118: 548–57
   PubMed Web of Science ®Google Scholar
• Wong R CW, Favaloro E J, Pollock W, et al. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology 2004; 36: 182–92
   PubMed Web of Science ®Google Scholar
• Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations—a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575–83
   PubMed Web of Science ®Google Scholar
• Neogi T, Gladman D D, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006; 33: 1785–8
   PubMed Web of Science ®Google Scholar
• Derksen R H, Bast E J, Strooisma T, Jacobs J W. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis 2002; 61: 1099–102
   PubMed Web of Science ®Google Scholar
• Favaloro E J, Wong R CW, Silvestrini R, et al. A multi-laboratory peer-assessment quality assurance program based evaluation of anti-cardiolipin and beta-2-glycoprotein-1 antibody assays. Semin Thromb Hemost 2005; 31: 73–84
   PubMed Web of Science ®Google Scholar
• Reber G, Schousboe I, Tincani A, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66–73
   PubMed Web of Science ®Google Scholar
• Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodies—when and how should they be measured?. Thromb Res 2004; 114: 527–31
   PubMed Web of Science ®Google Scholar
• Wasmuth J C, Oliver y Minarro D, Homrighausen A, et al. Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. Clin Chem 2002; 48: 1004–10
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Khamashta M A, Koike T, Matsuura E, Hughes G RV. Beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453–61
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Tsutsumi A, Atsumi T, et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 1999; 42: 2461–70
   PubMed Web of Science ®Google Scholar
• Wong R CW, Wilson R J, Pollock W, Steele R H, Gillis D. Anti-cardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology 2004; 36: 174–81
   PubMed Web of Science ®Google Scholar
• Wong R CW, Gillis D, Adelstein S, et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004; 36: 63–68
   PubMed Web of Science ®Google Scholar
• Merrill J T. Which antiphospholipid antibody tests are most useful?. Rheum Dis Clin North Am 2001; 27: 525–49
   PubMed Web of Science ®Google Scholar
• Triplett D A. Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126: 1424–9
   PubMed Web of Science ®Google Scholar
• Kahles T, Humpich M, Steinmetz H, Sitzer M, Lindhoff-Last E. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke. Rheumatology (Oxford) 2005; 44: 1161–5
   PubMed Web of Science ®Google Scholar
• Samarkos M, Davies K A, Gordon C, Loizou S. Clinical significance of IgA anticardiolipin and anti-beta(2)-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006; 25: 199–204
   PubMed Web of Science ®Google Scholar
• Carmo-Pereira S, Bertolaccini M L, Escudero-Contreras A, Khamashta M A, Hughes G R. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003; 62: 540–3
   PubMed Web of Science ®Google Scholar
• Lee R M, Branch D W, Silver R M. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001; 185: 748–53
   PubMed Web of Science ®Google Scholar
• Greco T P, Amos M D, Conti-Kelly A M, Naranjo J D, Ijdo J W. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus 2000; 9: 33–41
   PubMed Web of Science ®Google Scholar
• Lakos G, Kiss E, Regeczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999; 117: 574–9
   PubMed Web of Science ®Google Scholar
• Yamada H, Tsutsumi A, Ichikawa K, et al. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum 1999; 42: 2727–8
   PubMed Web of Science ®Google Scholar
• Arkin C F, Adcock D M, Ernst D J, et al. NCCLS. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays; Approved Guideline—Fourth Edition. NCCLS, Wayne, PA 2003, NCCLS document H21-A4
   Google Scholar
• Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185–90
   PubMed Web of Science ®Google Scholar
• ASCIA Guidelines—Uncertainty of Measurement (inter-batch/lot precision). Available online at: http://www.allergy.org.au/pospapers/Uncertainty_of_Measurement.htm (accessed 27 June 2005)
   Google Scholar
• Asherson R A, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62: 388–93
   PubMed Web of Science ®Google Scholar
• Lewis D A, Pound M L, Ortel T L. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-β2-glycoprotein-1 ELISAs. J Thromb Haemost 2006; 4: 265–7
   PubMed Web of Science ®Google Scholar
• Wong R C, Favaloro E J. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs: a rebuttal. J Thromb Haemost 2006; 4: 1434–5
   PubMed Web of Science ®Google Scholar
• Lewis D A, Pound M L, Ortel T L. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs. Reply to a rebuttal. J Thromb Haemost 2006; 4: 1435–7
   Web of Science ®Google Scholar
• Agopian M S, Boctor F N, Peter J B. False-positive test result for IgM anticardiolipin antibody due to IgM rheumatoid factor. Arthritis Rheum 1988; 31: 1212–3
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–32
   PubMed Web of Science ®Google Scholar